Second Line Sorafenib After Pazopanib in Patients With RCC
Status:
Terminated
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
- Retrospective studies showed Sorafenib's efficacy as second line treatment after a
Tyrosine Kinase Inhibitor (TKI).
- Currently there is no standard of treatment in 2nd line for patients treated in first
line with pazopanib for metastatic Renal Cell Carcinoma (mRCC).
- With this trial we evaluate the efficacy of sorafenib as second line of treatment in
patients treated with pazopanib for mRCC.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano